Your browser doesn't support javascript.
loading
Combination of EP4 antagonist MF-766 and anti-PD-1 promotes anti-tumor efficacy by modulating both lymphocytes and myeloid cells.
Wang, Yun; Cui, Long; Georgiev, Peter; Singh, Latika; Zheng, Yanyan; Yu, Ying; Grein, Jeff; Zhang, Chunsheng; Muise, Eric S; Sloman, David L; Ferguson, Heidi; Yu, Hongshi; Pierre, Cristina St; Dakle, Pranal J; Pucci, Vincenzo; Baker, James; Loboda, Andrey; Linn, Doug; Brynczka, Christopher; Wilson, Doug; Haines, Brian B; Long, Brian; Wnek, Richard; Sadekova, Svetlana; Rosenzweig, Michael; Haidle, Andrew; Han, Yongxin; Ranganath, Sheila H.
Afiliación
  • Wang Y; Department of Oncology Early Discovery, Merck & Co., Inc., Boston, Massachusetts, USA.
  • Cui L; Department of Quantitative Biosciences, Merck & Co., Inc., Boston, Massachusetts, USA.
  • Georgiev P; Department of Oncology Early Discovery, Merck & Co., Inc., Boston, Massachusetts, USA.
  • Singh L; Department of Oncology Early Discovery, Merck & Co., Inc., Boston, Massachusetts, USA.
  • Zheng Y; Department of Oncology Early Discovery, Merck & Co., Inc., Boston, Massachusetts, USA.
  • Yu Y; Department of Oncology Early Discovery, Merck & Co., Inc., Boston, Massachusetts, USA.
  • Grein J; Department of Genetics and Pharmacogenomics, Merck & Co., Inc., Boston, Massachusetts, USA.
  • Zhang C; Department of Genetics and Pharmacogenomics, Merck & Co., Inc., Boston, Massachusetts, USA.
  • Muise ES; Department of Genetics and Pharmacogenomics, Merck & Co., Inc., Boston, Massachusetts, USA.
  • Sloman DL; Department of Discovery Chemistry, Merck & Co., Inc., Boston, Massachusetts, USA.
  • Ferguson H; Department of Pharmaceutical Science, Merck & Co., Inc., Boston, Massachusetts, USA.
  • Yu H; Department of Pharmaceutical Science, Merck & Co., Inc., Boston, Massachusetts, USA.
  • Pierre CS; Department of Oncology Early Discovery, Merck & Co., Inc., Boston, Massachusetts, USA.
  • Dakle PJ; Department of Oncology Early Discovery, Merck & Co., Inc., Boston, Massachusetts, USA.
  • Pucci V; Department of Pharmacokinetics, Pharmacodynamics & Drug Metabolism, Merck & Co., Inc., Boston, Massachusetts, USA.
  • Baker J; Department of Pharmacokinetics, Pharmacodynamics & Drug Metabolism, Merck & Co., Inc., Boston, Massachusetts, USA.
  • Loboda A; Department of Genetics and Pharmacogenomics, Merck & Co., Inc., Boston, Massachusetts, USA.
  • Linn D; Department of Quantitative Biosciences, Merck & Co., Inc., Boston, Massachusetts, USA.
  • Brynczka C; Dept. Safety and Exploratory Pharmacology, Safety Assessment and Laboratory Animal Resources, Merck & Co., Inc., Boston, Massachusetts, USA.
  • Wilson D; Department of Genetics and Pharmacogenomics, Merck & Co., Inc., Boston, Massachusetts, USA.
  • Haines BB; Department of Quantitative Biosciences, Merck & Co., Inc., Boston, Massachusetts, USA.
  • Long B; Department of Quantitative Biosciences, Merck & Co., Inc., Boston, Massachusetts, USA.
  • Wnek R; Department of Translational Biomarkers, Merck & Co., Inc., Boston, Massachusetts, USA.
  • Sadekova S; Department of Oncology Early Discovery, Merck & Co., Inc., Boston, Massachusetts, USA.
  • Rosenzweig M; Department of Oncology Early Discovery, Merck & Co., Inc., Boston, Massachusetts, USA.
  • Haidle A; Department of Discovery Chemistry, Merck & Co., Inc., Boston, Massachusetts, USA.
  • Han Y; Department of Discovery Chemistry, Merck & Co., Inc., Boston, Massachusetts, USA.
  • Ranganath SH; Department of Oncology Early Discovery, Merck & Co., Inc., Boston, Massachusetts, USA.
Oncoimmunology ; 10(1): 1896643, 2021 03 18.
Article en En | MEDLINE | ID: mdl-33796403
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Linfocitos T CD8-positivos / Subtipo EP4 de Receptores de Prostaglandina E Tipo de estudio: Prognostic_studies Idioma: En Revista: Oncoimmunology Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Linfocitos T CD8-positivos / Subtipo EP4 de Receptores de Prostaglandina E Tipo de estudio: Prognostic_studies Idioma: En Revista: Oncoimmunology Año: 2021 Tipo del documento: Article